Open access
Open access
Powered by Google Translator Translator

Oncology – Head and Neck

Noninferiority RCT | Induction chemotherapy regimen of docetaxel plus cisplatin vs. docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma.

6 Sep, 2022 | 14:29h | UTC

Induction chemotherapy regimen of docetaxel plus cisplatin versus docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Preliminary results of an open-label, noninferiority, multicentre, randomised, controlled phase 3 trial – eClinicalMedicine

 


Guideline | Patient preparation and radiation protection guidance for adult patients undergoing radioiodine treatment for thyroid cancer.

1 Sep, 2022 | 11:53h | UTC

Patient Preparation and Radiation Protection Guidance for Adult Patients Undergoing Radioiodine Treatment for Thyroid Cancer in the UK – Clinical Oncology

 


RCT | In patients with low-risk nasopharyngeal carcinoma, radiotherapy alone was noninferior to radiotherapy plus concurrent chemoradiotherapy on survival without disease relapse at 3 years.

25 Aug, 2022 | 12:13h | UTC

Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial – JAMA (free for a limited period)

Video Editor’s Note: Radiotherapy With vs Without Chemoradiotherapy in Low-risk Nasopharyngeal Carcinoma – JAMA

 


The contemporary management of cancers of the sinonasal tract in adults.

16 Aug, 2022 | 13:39h | UTC

The contemporary management of cancers of the sinonasal tract in adults – CA: A Cancer Journal for Clinicians

 


Guideline | Pediatric differentiated thyroid carcinoma.

29 Jul, 2022 | 12:31h | UTC

Paediatric differentiated thyroid carcinoma: a UK National Clinical Practice Consensus Guideline – Endocrine-Related Cancer

 


Phase 2 RCT | Deintensified chemoradiotherapy for pretreatment Epstein-Barr Virus DNA-selected low-risk locoregionally advanced nasopharyngeal carcinoma.

19 Jul, 2022 | 12:58h | UTC

Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentaries:

#VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma – Physician’s Weekly

Intensity-Modulated Radiotherapy Plus 2 Cycles of Concurrent Cisplatin Improved Low-Risk LA-NPC Outcomes – Cancer Network

 

Commentary on Twitter

 


Evaluation of the molecular landscape of pediatric thyroid nodules and use of a multigene genomic classifier in children.

8 Jul, 2022 | 11:20h | UTC

Evaluation of the Molecular Landscape of Pediatric Thyroid Nodules and Use of a Multigene Genomic Classifier in Children – JAMA Oncology

 

Commentaries on Twitter

 


Induction chemotherapy in nasopharyngeal carcinoma- A systematic review of phase III clinical trials.

23 Jun, 2022 | 09:54h | UTC

Induction chemotherapy in nasopharyngeal carcinoma- A systematic review of phase III clinical trials – Cancer Treatment and Research Communications

 


Health Technology Assessment: Molecular testing for thyroid nodules of indeterminate cytology.

25 May, 2022 | 10:42h | UTC

Molecular Testing for Thyroid Nodules of Indeterminate Cytology: A Health Technology Assessment – Ontario Health Technology Assessment Series

 


M-A: Complication rates of total thyroidectomy vs. hemithyroidectomy for treatment of papillary thyroid microcarcinoma.

11 May, 2022 | 10:59h | UTC

Complication Rates of Total Thyroidectomy vs Hemithyroidectomy for Treatment of Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-analysis – JAMA Otolaryngology-Head & Neck Surgery (link to abstract – $ for full-text)

 

Commentary on Twitter

 


ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer.

5 May, 2022 | 10:16h | UTC

ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer – Annals of Oncology

 


RCT: Effect of capecitabine maintenance therapy plus best supportive care vs. best supportive care alone on progression-free survival among patients with newly diagnosed metastatic nasopharyngeal carcinoma who had received induction chemotherapy.

27 Apr, 2022 | 07:44h | UTC

Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy: A Phase 3 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCT: Sintilimab vs. placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic esophageal squamous cell carcinoma.

20 Apr, 2022 | 09:28h | UTC

Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial – The BMJ

 

Commentary on Twitter

 


Development and validation of machine learning models for predicting occult nodal metastasis in early-stage oral cavity squamous cell carcinoma.

20 Apr, 2022 | 09:14h | UTC

Development and Validation of Machine Learning Models for Predicting Occult Nodal Metastasis in Early-Stage Oral Cavity Squamous Cell Carcinoma – JAMA Network Open

 

Commentary on Twitter

 


Development and validation of a decision analytical model for posttreatment surveillance for patients with oropharyngeal carcinoma.

14 Apr, 2022 | 07:52h | UTC

Development and Validation of a Decision Analytical Model for Posttreatment Surveillance for Patients With Oropharyngeal Carcinoma – JAMA Network Open

 


RCT: Effect of induction chemotherapy with Paclitaxel, Cisplatin, and Capecitabine vs. Cisplatin and Fluorouracil on failure-free survival for patients with stage IVA to IVB Nasopharyngeal Carcinoma.

28 Mar, 2022 | 08:36h | UTC

Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

Commentary: Triplet Induction Regimen Bests Doublet for Nasopharyngeal Carcinoma — Three drugs reduced risk of disease failure, but longer follow-up needed to assess OS – MedPage Today (free registration required)

 

Commentary on Twitter

 


SEOM-TTCC clinical guideline in nasopharynx cancer.

25 Mar, 2022 | 08:20h | UTC

SEOM-TTCC clinical guideline in nasopharynx cancer (2021) – Clinical and Translational Oncology

 


Trends in HPV–associated cancers, demographic characteristics, and vaccinations in the US, 2001-2017.

17 Mar, 2022 | 08:16h | UTC

Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations in the US, 2001-2017 – JAMA Network Open

Author Interview: Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations

Related:

[Not published yet] Single-dose HPV vaccine highly effective, researchers say – “Results of randomized controlled trial in Kenya bring new energy to eliminate cervical cancer worldwide”.

A national HPV vaccination program in England was associated with an estimated reduction in cervical cancer rates of 87% for those offered the vaccine at age 12–13 years.

Three-year follow-up of 2-dose versus 3-dose HPV vaccine

Nationwide cohort study in Sweden shows HPV vaccination linked to reduced risk of invasive cervical cancer

CDC: 92% of Human Papillomavirus–Attributable Cancers can be Targeted by HPV Vaccination

Meta-Analysis: Population-level Impact of HPV Vaccination Programs

 


RCT: In patients with low-risk thyroid cancer, thyroidectomy without ablation radioiodine was noninferior to thyroidectomy with ablation radioiodine at 3 years.

10 Mar, 2022 | 10:59h | UTC

Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: New research casts doubt on a cornerstone of thyroid cancer treatment – STAT

 

Commentary on Twitter

 


RCT: Elective upper-neck vs. whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma.

9 Mar, 2022 | 08:17h | UTC

Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentaries:

Elective Upper-Neck vs Whole-Neck Irradiation in Nasopharyngeal Carcinoma – The ASCO Post

Lower Neck-Sparing RT Succeeds in Nasopharyngeal Carcinoma— Phase III trial also shows that upper-neck irradiation leads to fewer late toxicities – MedPage Today (link to abstract – $ for full-text)

 


RCT: In operated patients with head and neck cancer, chemoradiotherapy with weekly cisplatin is noninferior to 3-weekly cisplatin and is associated with reduced toxicity.

3 Mar, 2022 | 08:11h | UTC

Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial – Journal of Clinical Oncology

 

Commentary from the author on Twitter

 


HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management.

1 Mar, 2022 | 08:30h | UTC

HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management – Nature Reviews Clinical Oncology (if the link is paywalled, try this one)

 


Consensus Statement: Head and neck cancer survivorship.

16 Feb, 2022 | 08:49h | UTC

Head and neck cancer survivorship consensus statement from the American Head and Neck Society – Laryngoscope Investigative Otolaryngology

Related:

Head and Neck Cancer Survivorship Care Guideline

American Cancer Society Head and Neck Cancer Survivorship Care Guideline

 


ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?

11 Feb, 2022 | 08:23h | UTC

2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? – European Thyroid Journal

 


RCT: Apatinib improves outcomes compared to placebo in patients with locally advanced or metastatic, radioactive iodine–refractory differentiated thyroid cancer.

10 Feb, 2022 | 09:56h | UTC

Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine–Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial – JAMA Oncology

 

Commentary on Twitter

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.